Get the Stockscreener App
2.745
1.96%
-0.055
After Hours:
2.78
0.035
+1.28%
Entera Bio Ltd stock is traded at $2.745, with a volume of 775.18K.
It is down -1.96% in the last 24 hours and down -20.89% over the past month.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
See More
Previous Close:
$2.80
Open:
$2.91
24h Volume:
775.18K
Relative Volume:
0.44
Market Cap:
$475.27M
Revenue:
$42,000
Net Income/Loss:
$-12.38M
P/E Ratio:
-10.42
EPS:
-0.2634
Net Cash Flow:
$-9.61M
1W Performance:
-7.26%
1M Performance:
-20.89%
6M Performance:
+132.63%
1Y Performance:
+53.35%
1-Day Range:
$2.70
$2.91
1-Week Range:
$2.70
$3.03
52-Week Range:
$0.91
$4.20
Entera Bio Ltd Stock (ENTX) Company Profile
Name
Entera Bio Ltd
Sector
Industry
Phone
972-2-532-7151
Address
KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM
Compare ENTX vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENTX
Entera Bio Ltd
|
2.745 | 475.27M | 42,000 | -12.38M | -9.61M | -0.2634 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-22-21 | Initiated | Aegis Capital | Buy |
Entera Bio Ltd Stock (ENTX) Latest News
Form PRE 14A ENTERA BIO LTD. For: 27 September By Investing.com - Investing.com Canada
Entera Bio Initiated at Buy by Guggenheim - Moomoo
Guggenheim Initiates Entera Bio at Buy With $11 Price Target - marketscreener.com
Guggenheim initiates Entera Bio stock with buy rating on oral peptide platform - Investing.com India
After raising about $275 million, Entera Bio (ENTX) asks shareholders to expand its share incentive plan. - Stock Titan
Entera Bio Receives New Overweight Rating From Cantor Fitzgerald (NASDAQ: ENTX) - TipRanks
Entera Bio Ltd. (ENTX) Initiated Overweight by Cantor; DCF Target $12.58 - TradingView
Entera Receives $9 Price Target And New 'Outperform' Rating From Leerink Partners (NASDAQ: ENTX) - Menafn
Entera Receives $9 Price Target and New ‘Outperform’ Rating From Leerink Partners (NASDAQ: ENTX) - TipRanks
Leerink Partners Initiates Entera Bio(ENTX.US) With Buy Rating, Announces Target Price $9 - Moomoo
Entera Bio Ltd. (NASDAQ:ENTX) Initiated at Outperform by Leerink With $9 Target - TradingView
Entera Receives $9 Price Target and New 'Outperform' Rating From Leerink Partners (NASDAQ: ENTX) - Benzinga
Entera Bio Stock Price Forecast. Should You Buy ENTX? - StockInvest.us
Entera Bio Ltd. WarrantADR (ENTXW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Entera Bio Ltd. SEC Filing (Aug 31, 2026) - Stock Titan
ENTX Q2 2026 Earnings: Wider-than-Expected Loss of -$0.14 Per Share on Zero RevenueRevenue Guidance Update - careplusvn.com
Entera to Participate in Upcoming Fall Investor Conferences - Yahoo Finance
Entera (ENTX) Earnings Reading: Reported EPS Misses Expectations on the Day; Stock Move: Shares Move Higher 5.88%Quarterly Profit Report - vinanet.vn
Entera Bio (NASDAQ:ENTX) Stock Price Up 5.1%Here's Why - MarketBeat
Entera Bio CEO Miranda Toledano to speak at Canaccord Genuity conference - scanx.trade
Entera (ENTX) Earnings Snapshot: Profit Per Share Falls Below Its Benchmark in the Reported Period - vinanet.vn
Entera (ENTX) Results Review: EPS Misses Its Estimate; Market Move: Shares Finish 4.84% Up in the Current Update - vinanet.vn
Entera Bio appoints new chief medical officer - The Globe and Mail
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation - Sahm
symbol__ Stock Quote Price and Forecast - CNN
Entera Bio appoints Riccardo Camisasca as chief medical officer - Investing.com
Entera Bio Names New Chief Medical Officer Ahead of EB613 Phase 3 Start - Minichart
Form 8K Entera Bio Ltd. For: 18 August By Investing.com - Investing.com India
Entera Bio appoints Riccardo Camisasca as chief medical officer By Investing.com - Investing.com Canada
A drug developer with 30-plus years joins Entera for a planned osteoporosis Phase 3 trial - Stock Titan
Renaissance Technologies LLC Buys 365,441 Shares of Entera Bio Ltd. $ENTX - MarketBeat
ENTX Q2 2026 Earnings: EPS Miss of 71.6% and Zero Revenue – Shares Move HigherEPS Growth Report - dars.gov.et
ENTX Q2 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue Pipeline InvestmentEPS Guidance Update - careplusvn.com
Entera Bio Ltd (ENTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA Agreement - MarketBeat
Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Increases By 286.7% - MarketBeat
ENTX Q2 2026 Earnings: Wider-Than-Expected Loss per Share Reflects Clinical-Stage InvestmentGeographic Revenue Trends - careplusvn.com
Entera Bio at Canaccord Genuity: oral osteoporosis push advances By Investing.com - Investing.com Canada
Entera Bio (ENTX) completes $275M Rule 506(b) private offering of shares and warrants - Stock Titan
Entera Bio at Canaccord Genuity: oral osteoporosis push advances - Investing.com
Entera Bio shares slip as Q2 loss comes in wider than expected - Yahoo Finance
Entera Bio misses Q2 estimates, reports wider loss By Investing.com - Investing.com Nigeria
Entera Bio misses Q2 estimates, reports wider loss - Investing.com
Entera Bio Ltd. (ENTX) stock price, news, quote and history - au.finance.yahoo.com
Entera Bio (NASDAQ:ENTX) Upgraded to Sell at Wall Street Zen - MarketBeat
Entera Bio raises $275M in oversubscribed placement, shares rebound on funding news - scanx.trade
Entera Bio (NASDAQ:ENTX) Announces Earnings Results - MarketBeat
Entera Bio Q2 EPS misses estimate as net loss widens to $7.3 million - scanx.trade
Entera Bio Strengthens Finances to Advance Oral Peptide Pipeline - TipRanks
Entera Announces Second Quarter 2026 Financial Results and Business Updates - The Manila Times
Entera Bio Reports Q2 2026 Loss and $275 Million Private Placement - Moomoo
Entera Bio Ltd Stock (ENTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):